A Single- and Multiple-Ascending Dose, Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Study of LY2969822 in Healthy Subjects
Latest Information Update: 25 Feb 2019
At a glance
- Drugs LY 2969822 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2015 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015, as reported by ClinicalTrials.gov.
- 25 Feb 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2015, as reported by ClinicalTrials.gov.